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Problems of assessment of endogenous prostaglandin
production
Endogenous prostaglandin production is often
determined by measuring the plasma or urine con-
centrations of these prostanoids or their main
metabolites [1]. The metabolism of most prostaglan-
dins has been elucidated to ascertain which parame-
ter is most suitable for determination of total body
synthesis of the parent compound (for review, see
Ref. 2). These studies demonstrated that metabo-
lism of the "classical" prostaglandins E2 and F2a
within the lung occurs very rapidly so that they are
almost completely degraded during one passage
through the circulation [31. It has been shown that
90 seconds after the i.v. administration of labeled
PGE2 only about 3% of the injected dose was
present in blood as PGE2, whereas the half-life of
1 l-hydroxy-9, 15-diketo-prost-5-enoic acid, one of
its circulating metabolites, was about 8 mm [4].
Similar results were obtained for PGF2a [5]. This
led to the conclusion that urinary excretion of PGE2
or PGF2a probably is not an indicator of total body
synthesis. This was confirmed by the observation
that after the i.v. administration of PGE, into man
no increase in urinary PGE2 excretion could be
measured [4]. The main urinary metabolite of PGE1
and PGE, in man is 7a-hydroxy-5,ll-diketo-te-
tranor-prosta- 1, l6-dioic acid [41 and that of PGF2
is 5 ,7-dihydroxy- 11 -keto-tetranor-prosta- 1,1 6-dioic
acid [6]. These metabolites now are regarded as
indicators of total body synthesis of PGE1 and
PGE2 or PGF2a, respectively.
A change in urinary excretion of one of these
metabolites, however, does not necessarily prove a
change in total body synthesis of the parent com-
pound because the same effect also could be caused
by a shift of its metabolic pattern. It would appear
preferable, therefore, to determine several urinary
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metabolites of a prostanoid for assessment of its
total body synthesis.
The metabolic studies showed that excretion of
PGE2 and PGF2a into urine does not result from
circulating levels of these prostaglandins. In addi-
tion, stop-flow experiments carried out by our
group have shown that PGE2 and PGF2 are secret-
ed into the loop of Henle [7]. Therefore, it was
concluded that urinary excretion of both prostan-
oids predominantly reflects their intrarenal synthe-
sis [7, 8].
Numerous studies have since used the measure-
ment of urinary PGE2 and PGF2a to assess the rate
of renal synthesis of these prostanoids. Apart from
significant methodologic problems showing discrep-
ancies between values measured by the reference
method (gas chromatography mass spectrometry)
and radioimmunoassay [1], it can be expected that
many factors including urinary pH and flow rate can
affect this parameter.
In contrast to the "classical prostaglandins,"
until recently no information existed about metabo-
lism of prostacyclin (PGI2) in man. Studies per-
formed in several animals have shown that this
prostanoid is not metabolized during passage
through the lung [9, 10]. Because of its chemical
instability, prostacyclin is rapidly hydrolyzed to 6-
keto-PGF1a under physiologic conditions [11].
Therefore, it has been assumed that determination
of 6-keto-PGF1a in plasma or urine should reflect
endogenous prostacyclin production. In addition to
nonenzymatic hydrolysis to 6-keto-PGF1a, termina-
tion of the biological activity of prostacyclin might
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occur by metabolism within the kidney [12] (Ro-
senkranz et al, submitted for publication), the liver
[13], or the vessel wall [14], resulting in metabolites
other than 6-keto-PGF1a. This would lead to the
conclusion that 6-keto-PGF1, like the "classical"
prostaglandins, is not a useful parameter of endoge-
nous prostacyclin production. The following discus-
sion centers around the problem of assessment of
renal and total body prostacyclin synthesis.
Metabolism of prostacyclin and 6-keto-PGFj, in man
To define the relevance of urinary 6-keto-PGF1a
excretion, investigators have considered it neces-
sary, like for PGE2 and PGF2a, to study the metabo-
lism of prostacyclin and 6-keto-PGF1a. Therefore,
our group investigated the urinary metabolites of
prostacyclin and 6-keto-PGF1a in man [15, 16].
Tritiated and tetradeuterated prostacyclin, as well
as unlabeled prostacyclin, was infused i.v. into
healthy male volunteers at the rates of I and 5
ng/kg/min, respectively. In separate experiments,
tritiated or unlabeled 6-keto-PGF1a was infused at
the rates of 0.04 and 420 ng/kg/min. When com-
pared with the infusion rates necessary for satura-
tion of the metabolizing enzymes of PGE2 or
PGF2a, the infusion rates of I and 0.04 ng/kg/min
chosen for the labeled compounds were below this
level [15]. Our study demonstrated that after the
administration of labeled prostacyclin, labeled 6-
keto-PGF1a could be detected in urine after extrac-
tion and chromatography by use of gas chromatog-
raphy mass spectrometry (GCMS) (Fig. 1).
In addition to the fragments m/z 614 (M-l5),
598 (M-31), 558 (M-7l), 508 (M-31—90), 468
(M-71—90), 418 (M-31-2 x 90), and 378 (M-71-
2 x 90), the deuterated ions mlz 618, 602, 512, and
422 were present, showing that this material result-
ed from the infused deuterated prostacyclin and did
not reflect endogenous renal prostacyclin synthesis.
The fragments obtained after cleavage of the lower
chain (M -71) did not show a corresponding deuter-
ated fragment because the molecule was labeled in
the lower chain. The material from which this mass
spectrum was obtained represented 14.2% of the
radioactivity recovered from high-pressure liquid
chromotography (HPLC). Thus, circulating prosta-
cyclin is partly excreted into urine as 6-keto-PGF1a.
This study further revealed that the major urinary
metabolite of prostacyclin in man is not 6-keto-
PGF1a, but rather its f3- and o-oxidized analogues,
dinor-6-keto-PGF1 and dinor-6, 1 5-diketo- 13, 14-di-
hydro-20-carboxyl-PGF1, corresponding to 20.5
and 19.7% of the radioactivity, respectively. In
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Fig. 1. Mass spectrum of deuterated6-keto-PGF10, obtainedfrom
human urine after the Lv. infusion of tetradeuterated and
tritiated PGI2. The urine was chromatographed, and the result-
ing peaks were derivatized to the methoxime methyl ester
trimethyl silyl ether and were analyzed by gas chromatography
mass spectrometry using a glass capillary column.
addition, dinor-6, I 5-diketo- 13, 14-dihydro-PGFj
and 6, 15-diketo-13, 14-dihydro-PGF1 (6.8 and
1.4%, respectively) could be detected in urine [15].
The same metabolites also could be identified from
urine after infusion of 6-keto-PGF1a with the rela-
tive amounts of 6.8% (6-keto-PGF1,), 22.4% (dinor-
6-keto-PGF1a), 7.0% (dinor-6, I 5-diketo- 13,1 4-dihy-
dro-20-carboxyl-PGF1a), 5.4% (dinor-6, 1 5-diketo-
13, l4-dihydro-PGF1), and 5.7% (6, 15-diketo-l3, 14-
dihydro-PGFj) [15]. The similarity of both patterns
of metabolites suggests that circulating prostacyclin
first is hydrolyzed to 6-keto-PGF1 and partly me-
tabolized further by 13- and to-oxidation, 15-hy-
droxydehydrogenation, and reduction of the double
bond at Cl3. These enzymatic mechanisms have
also been described for several other prostanoids
[121, including prostacyclin in the rat [17, 18] These
metabolic studies demonstrate that urinary 6-keto-
PGF1a can result from circulating prostacyclin or 6-
keto-PGF1a. Other studies have shown, however,
that the renal cortex [19], the glomeruli [20, 21], and
the collecting duct [22] are able to convert arachi-
donic acid to prostacyclin. Therefore, it is still not
clear whether 6-keto-PGF1a detected in urine under
physiologic conditions really represents total body
prostacyclin synthesis or whether it represents re-
nal prostacyclin production.
Specificity of urinary prostacyclin metabolites for
intrarenal synthesis
Studies in the perfused rabbit kidney [12] have
shown that dinor-6-keto-PGF and dinor-6, 15-di-
keto- 13, l4-dihydro-PGF1, could be detected in the
effluent collected from the renal vein after addition
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of labeled prostacyclin to the perfusion medium.
But not enough radioactivity could be collected
from the ureteral effluent to determine the metabol-
ic profile. Therefore, we performed experiments
(Rosenkranz et a!, submitted for publication) to
determine whether a metabolite could be identified
that is specific for the urinary compartment and
originates from within the kidney.
Isolated rabbit kidneys were perfused with a
solution to which prostacyclin was added continu-
ously at the rate of 0.23 pgImin for 1 hour. Subse-
quently, the kidney was perfused for another 15 mm
with the perfusate only. By this technique, 2.3% of
the total radioactivity could be recovered from the
ureteral effluent. The renal venous and the ureteral
effluents were extracted and chromatographed. The
materials belonging to the peaks obtained by
Porasil HPLC were derivatized to the methoxime
methyl ester trimethylsilyl ether and analyzed by
GCMS. Of the radioactivity recovered from the
ureteral and venous effluent, 9.6% and 9.1%, re-
spectively, resulted in the fragmentation pattern
mlz 586, 570, 530, 480, 440, 421, 390, and 350,
corresponding to M -15, M -31, M ;f
-71, M -90—
31, M-90—71, M-2x90, M-2x90-31, and M-
2 x 90—71 of dinor-6-keto-PGF1a [16]. In addition,
39.2% and 58.2% of the ureteral and venous efflu-
ent, respectively, could be identified as 6-keto-
PGF1a by use of GCMS. Further smaller peaks
were obtained on HPLC, which all contained less
than 10% of the radioactivity each.
Thus, in this experiment, no metabolite of prosta-
cyclin specific for intrarenal synthesis of prostacy-
din could be identified from the ureteral effluent. In
addition, these results show that urinary dinor-6-
keto-PGF1a, one of the major urinary metabolites of
prostacyclin after its Lv. administration in man, can
partly result from renal metabolism of prostacyclin.
Origin of urinary 6-keto-PGF,,.
Our studies about metabolism of prostacyclin and
6-keto-PGF, in man have demonstrated that circu-
lating 6-keto-PGF1 can be excreted into urine. But,
the question of the origin of 6-keto-PGF1a detected
in urine under physiologic conditions still remains
unanswered. Besides glomerular filtration, the most
likely mechanism for the excretion of 6-keto-PGF1a
would be an active secretion by the organic acid
secretory pathway because it has been shown that
this route plays an important role in the excretion of
PGE2, reaching the kidney via the renal artery [23].
We performed experiments in the dog to determine
the importance of the acid secretory pathway for 6-
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Fig. 2. Urinary excretion of a bolus of tritiated PGE2 together
with inulin administered into one renal artery of the anesthetized
dog. Urine was collected in 20-second fractions and analyzed for
radioactivity and inulin. Top: control; bottom: after pretreatment
with probenecid.
keto-PGFJQ (Kitajima et al, submitted for publica-
tion). A bolus of inulin (100 mg) and tritiated PGE2
or 6-keto-PGF1a (0.5 pCi each) was administered
into one renal artery of the anesthetized dog before
and after pretreatment with probenecid (25 mg/kg),
a blocker of the organic acid secretory pathway.
Urine was collected in 20-second periods and ana-
lyzed for radioactivity and inulin. When PGE2 was
administered, excretion of radioactivity was de-
layed with respect to the inulin peak (Fig. 2). Inulin
served as a marker for glomerular filtration. Thus,
some mechanism that is more time consuming than
mere filtration is involved in the excretion of PGE2.
As pretreatment with probenecid abolished this
delayed portion of the radioactive peak, it was
concluded that PGE2 is partly excreted via the
organic acid secretory pathway as previously de-
scribed [23].
The same experiment was carried out for 6-keto-
PGF1a in the anesthetized dog. The radioactive
material appeared in the same fractions as the inulin
peak (Fig. 3). Probenecid affected neither excretion
of radioactivity significantly nor excretion of endog-
enous 6-keto-PGF1a as determined by GCMS.
These studies show that 6-keto-PGF1a, in con-
trast to PGE2, is not excreted via the organic acid
secretory pathway.
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Conclusion
These studies lead to the conclusion that urinary
6-keto-PGF1a can originate from circulating prosta-
cyclin or 6-keto-PGF1a. Renal excretion of 6-keto-
PGF1c. obviously occurs mainly by glomerular fil-
tration, whereas the organic acid secretory pathway
does not play an important role. But no information
exists so far about the excretion of 6-keto-PGF1a at
another site of the tubule. Therefore, further studies
are required to define whether 6-keto-PGF1a detect-
ed in urine mainly results from circulating prostacy-
din as suggested by our results or from the kidney.
Finally, the data presented strongly suggest that
the determination of dinor-6-keto-PGF1a or dinor-
6, 15-diketo- 13, 14-dihydro-20-carboxyl-PGF1, the
major metabolites of prostacyclin in human urine,
represents better parameters for total body prosta-
cyclin production in man than does 6-keto-PGF1.
The determination of these metabolites together
with 6-keto-PGF1a can give more precise informa-
tion than does the determination of a single parame-
ter because these three compounds reflect about
50% of the metabolites of prostacyclin in human
urine [14].
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Fig. 3. Urinary excretion of tritiated 6-keto-PGF1,, and inulin.
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